ABOUT THIS EPISODE
Can diseases associated with abnormal gene expression be treated without permanently rewriting DNA?
Programmable epigenome editing is opening new possibilities for precision therapeutics by enabling targeted gene activation, repression, and regulation without intentionally modifying underlying DNA sequences.
In this episode of Frost & Sullivan’s Growth Podcast, we explore five questions shaping the future of programmable epigenome editing, examining how CRISPR-based technologies, zinc finger proteins, epigenetic effectors, and emerging delivery systems are advancing therapeutic research.
The discussion explores potential applications across neuromuscular disorders, hepatitis B, cardiovascular and metabolic diseases, neurological conditions, and oncology. We also examine the development strategies of Epicrispr Biotechnologies, Modalis Therapeutics, Epitome Therapeutics, and Epigenic Therapeutics, highlighting how platform differentiation, therapeutic targeting, and clinical validation are influencing competition.
Two emerging growth opportunities take center stage: compact epigenome editors for targeted therapeutic delivery and AI-enabled target and guide selection. Both are creating opportunities for technology licensing, research efficiency, strategic partnerships, and therapeutic platform expansion.
👉 Can programmable epigenome editing enable disease treatment without changing DNA sequences?
👉 Which therapeutic applications and technology platforms are best positioned for clinical translation?
👉 How can delivery innovation, AI-enabled discovery, and strategic partnerships accelerate commercialization?
Designed for biotechnology companies, pharmaceutical developers, genomic medicine researchers, therapeutic platform providers, investors, and innovation leaders, this episode examines the technologies, clinical challenges, and strategic priorities shaping the future of programmable epigenome editing.
Explore related research:
https://www.frost.com | https://store.frost.com
Connect with our team:
hello@frost.com
Programmable epigenome editing is opening new possibilities for precision therapeutics by enabling targeted gene activation, repression, and regulation without intentionally modifying underlying DNA sequences.
In this episode of Frost & Sullivan’s Growth Podcast, we explore five questions shaping the future of programmable epigenome editing, examining how CRISPR-based technologies, zinc finger proteins, epigenetic effectors, and emerging delivery systems are advancing therapeutic research.
The discussion explores potential applications across neuromuscular disorders, hepatitis B, cardiovascular and metabolic diseases, neurological conditions, and oncology. We also examine the development strategies of Epicrispr Biotechnologies, Modalis Therapeutics, Epitome Therapeutics, and Epigenic Therapeutics, highlighting how platform differentiation, therapeutic targeting, and clinical validation are influencing competition.
Two emerging growth opportunities take center stage: compact epigenome editors for targeted therapeutic delivery and AI-enabled target and guide selection. Both are creating opportunities for technology licensing, research efficiency, strategic partnerships, and therapeutic platform expansion.
👉 Can programmable epigenome editing enable disease treatment without changing DNA sequences?
👉 Which therapeutic applications and technology platforms are best positioned for clinical translation?
👉 How can delivery innovation, AI-enabled discovery, and strategic partnerships accelerate commercialization?
Designed for biotechnology companies, pharmaceutical developers, genomic medicine researchers, therapeutic platform providers, investors, and innovation leaders, this episode examines the technologies, clinical challenges, and strategic priorities shaping the future of programmable epigenome editing.
Explore related research:
https://www.frost.com | https://store.frost.com
Connect with our team:
hello@frost.com
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of Frost & Sullivan Podcasts.
OTHER EPISODES IN THIS PODCAST
This episode of Frost & Sullivan’s Growth Podcast explores Calibration Services 2030: From Scheduled Checks to Digital Asset Assurance, examining how stricter compliance, more sophisticated instruments, digital tracking, and outsourcing are changing calibration and repair services.
We look at …
This episode of Frost & Sullivan’s Growth Podcast examines Industrial Control Systems 2032: Modernizing the Installed Base, focusing on how brownfield upgrades, software-defined automation, IT/OT convergence, and industrial edge computing are changing the control-system landscape.
Rather than …
Who is leading the race to commercialize next-generation tandem solar technology?
Perovskite-silicon tandem solar cells are advancing photovoltaic efficiency, creating opportunities to generate more electricity from limited installation space. But long-term reliability, manufacturing scalability, a…
What if the biggest regulatory threat to the chemical industry is also its biggest growth opportunity?
In this episode of Frost & Sullivan’s Growth Podcast, we explore how evolving global chemical regulations are reshaping the industry, examining how regulatory pressure is accelerating materia…
Disclaimer: The podcast and artwork embedded on this page are from Frost & Sullivan, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
